Related Experiment Video
Updated: Jun 28, 2026
06:57
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Human papillomavirus testing for primary cervical cancer screening.
Carolyn D Runowicz1, Stephanie Garozzo
1University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA. crunowicz@uchc.edu
Current Oncology Reports
|October 22, 2008
Summary
Primary human papillomavirus (HPV) testing is recommended for cervical cancer screening. This approach offers advantages over traditional cytology, especially with widespread HPV vaccination. Reassessing screening technologies is crucial for effective cervical cancer prevention.
Area of Science:
- Gynecologic Oncology
- Infectious Disease Epidemiology
- Public Health Screening
Background:
- Advances in understanding human papillomavirus (HPV) and cervical cancer pathogenesis.
- Established limitations of conventional cervical cytology methods.
- Increasing availability and proven efficacy of HPV testing technologies.
Purpose of the Study:
- To review randomized trials comparing primary HPV testing versus cervical cytology for cervical cancer screening.
- To analyze the influence of HPV vaccination on the performance and interpretation of cervical cytology screening.
Main Methods:
- Systematic review of recent randomized controlled trials.
- Comparative analysis of primary HPV testing versus cervical cytology.
- Evaluation of HPV vaccine impact on screening outcomes.
Main Results:
- Primary HPV testing demonstrates superior sensitivity in detecting high-grade cervical lesions compared to cytology.
- HPV testing facilitates extended screening intervals, potentially reducing over-detection and overtreatment.
- HPV vaccination is associated with a significant reduction in HPV prevalence and subsequent cytologic abnormalities.
Conclusions:
- Primary HPV testing represents a highly effective strategy for cervical cancer screening.
- Integration of HPV testing aligns with the goals of HPV vaccination programs for comprehensive prevention.
- Re-evaluation of current cervical cancer screening guidelines is warranted to incorporate HPV testing and vaccination data.
Related Concept Videos
01:23Genital Herpes
Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
01:28Herpes
Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...